

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
DISTRICT ADDRESS AND PHONE NUMBER 10903 New Hampshire Avenue Silver Spring, MD 20993 (301) 594-4695 Fax: (301) 594-4715		DATE(S) OF INSPECTION 2/27/2023-3/2/2023 FEI NUMBER 3007697975			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED David (NMI) Leleu, Director					
FIRM NAME EUROMI S.A.		STREET ADDRESS ZI des Plenesses, Rue Des Nouvelles Technologies 11			
CITY, STATE, ZIP CODE, COUNTRY Andrimont, Liege, 4821 Belgium		TYPE ESTABLISHMENT INSPECTED Manufacturer			
This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.					
<i>The observations noted in this Form FDA-483 are not an exhaustive listing of objectionable conditions. Under the law, your firm is responsible for conducting internal self-audits to identify and correct any and all violations of the quality system requirements.</i>					
DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1 An MDR report was not submitted within 30 days of receiving or otherwise becoming aware of information that reasonably suggests that a marketed device has malfunctioned and would be likely to cause or contribute to a death or serious injury if the malfunction were to recur. Specifically, your firm received device malfunction complaint number 2021-011 on 06/07/2021 which was not reported to the Agency within 30 days of awareness of the malfunction. This is a repeat observation from the FDA-483 issued on 04/27/2017.					
SEE REVERSE OF THIS PAGE		<table border="0" style="width: 100%;"> <tr> <td style="width: 60%;"> EMPLOYEE(S) SIGNATURE Michelle L Johnson, Investigator </td> <td style="width: 40%; text-align: center; vertical-align: bottom;"> Michelle L. Johnson Investigator Signed By: Michelle L. Johnson -S Date Signed: 03-03-2023 03-08-24 X _____ </td> </tr> </table>		EMPLOYEE(S) SIGNATURE Michelle L Johnson, Investigator	Michelle L. Johnson Investigator Signed By: Michelle L. Johnson -S Date Signed: 03-03-2023 03-08-24 X _____
EMPLOYEE(S) SIGNATURE Michelle L Johnson, Investigator	Michelle L. Johnson Investigator Signed By: Michelle L. Johnson -S Date Signed: 03-03-2023 03-08-24 X _____				
		DATE ISSUED 3/2/2023			

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
DISTRICT ADDRESS AND PHONE NUMBER 10903 New Hampshire Avenue Silver Spring, MD 20993 (301) 594-4695 Fax: (301) 594-4715		DATE(S) OF INSPECTION 2/27/2023-3/2/2023 FEI NUMBER 3007697975			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED David (NMI) Leleu, Director					
FIRM NAME EUROMI S.A.		STREET ADDRESS ZI des Plenesses, Rue Des Nouvelles Technologies 11			
CITY, STATE, ZIP CODE, COUNTRY Andrimont, Liege, 4821 Belgium		TYPE ESTABLISHMENT INSPECTED Manufacturer			
Annotations to Observations Observation 1: Promised to correct					
SEE REVERSE OF THIS PAGE		<table border="0" style="width: 100%;"> <tr> <td style="width: 60%;"> EMPLOYEE(S) SIGNATURE Michelle L Johnson, Investigator </td> <td style="width: 40%; text-align: center; vertical-align: bottom;"> Michelle L. Johnson Investigator Signed By: Michelle L. Johnson -S Date Signed: 03-03-2023 03:38:24 X _____ </td> </tr> </table>		EMPLOYEE(S) SIGNATURE Michelle L Johnson, Investigator	Michelle L. Johnson Investigator Signed By: Michelle L. Johnson -S Date Signed: 03-03-2023 03:38:24 X _____
EMPLOYEE(S) SIGNATURE Michelle L Johnson, Investigator	Michelle L. Johnson Investigator Signed By: Michelle L. Johnson -S Date Signed: 03-03-2023 03:38:24 X _____				
		DATE ISSUED 3/2/2023			

The observations of objectionable conditions and practices listed on the front of this form are reported:

1. Pursuant to Section 704(b) of the Federal Food, Drug and Cosmetic Act, or
2. To assist firms inspected in complying with the Acts and regulations enforced by the Food and Drug Administration.

Section 704(b) of the Federal Food, Drug, and Cosmetic Act (21 USC 374(b)) provides:

"Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgment, indicate that any food, drug, device, or cosmetic in such establishment (1) consists in whole or in part of any filthy, putrid, or decomposed substance, or (2) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. A copy of such report shall be sent promptly to the Secretary."